Fig. 2: Effects of sacubitril/valsartan compared to valsartan on primary endpoint. | Nature Communications

Fig. 2: Effects of sacubitril/valsartan compared to valsartan on primary endpoint.

From: Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial

Fig. 2

The primary endpoint in 78 participants. The effect estimates were presented in mean and 95% confidence intervals, with corresponding P values from one-way ANCOVA testing before and after adjustment for baseline covariates. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker.

Back to article page